SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that scientific presentations of the positive Phase 3 results from the recently completed placebo controlled study of Probuphine in the treatment of opioid addiction, along with additional data from an ongoing open-label Phase 3 trial of Probuphine, will be presented at the 2008 International Society of Addiction Medicine (ISAM) Congress annual meeting being held November 16-20, 2008 in Cape Town, South Africa. Probuphine is a novel, subcutaneous implant formulation of buprenorphine using Titan’s ProNeura technology to deliver six months of medication after a single administration.
